Aethlon Medical Files 8-K with March Quarter Financial Update

Rhea-AI Filing Summary

Aethlon Medical (Nasdaq:AEMD) filed a Form 8-K to furnish its press release announcing financial results for the quarter ended March 31, 2025. Reported under Items 2.02 and 7.01, the filing attaches the release as Exhibit 99.1 and states the information is provided under Regulation FD and not deemed “filed” for Exchange Act purposes. No detailed financial metrics, guidance, or strategic updates are included in the 8-K itself. Aside from furnishing the exhibit, the report discloses no material events likely to affect the company’s operating outlook or capital structure. Investors must review Exhibit 99.1 for the actual results.

false 0000882291 0000882291 2025-06-26 2025-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

Aethlon Medical, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11555 Sorrento Valley Road, Suite 203 San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (619) 941-0360

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	AEMD	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The information provided below in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) is incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On June 26, 2025, Aethlon Medical, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2025. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release, dated June 26, 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 27, 2025	Aethlon Medical, Inc.
	By:	/s/ James B. Frakes
	Name:	James B. Frakes Chief Executive Officer and Chief Financial Officer

3

FAQ

When did AEMD release its quarter-ended March 31 2025 results?

The company issued the press release on June 26 2025, as disclosed in the Form 8-K.

Which SEC form did Aethlon Medical use to disclose its Q1 2025 results?

Aethlon Medical furnished a Form 8-K under Items 2.02 (Results of Operations) and 7.01 (Regulation FD Disclosure).

Is the press release in this 8-K considered “filed” under the Exchange Act?

No. The company specifies the information is furnished, not filed, and thus isn’t subject to Section 18 liabilities.

Where can investors find the detailed financial figures for AEMD’s March 2025 quarter?

The numbers are contained in Exhibit 99.1 to the 8-K, the press release dated June 26 2025.